Category Archives: Embryonic Stem Cells


Stem Cell Clinic > Embryonic Stem Cells

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a…

By Embryonic Stem Cells

PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, and Denali Capital Acquisition Corp., a Cayman Islands corporation and special purpose acquisition company (Nasdaq: DECA, “SPAC”), today announced the signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Semnur up to $2.0 billion, subject to adjustment based on third-party fairness opinion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares that are redeemed prior to the completion of the business combination.

Read more from the original source:
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a...

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

By Embryonic Stem Cells

Planegg/Martinsried, July 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the Chinese Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1) and LAGE 1a (L Antigen Family Member-1a), both being well-recognized and validated cancer-testis antigens, expressed in multiple tumor types.

More:
Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

Olon Group Announces the Acquisition of GTP Bioways Group

By Embryonic Stem Cells

MILAN, July 03, 2024 (GLOBE NEWSWIRE) -- GTP Bioways Group is a French company operating as Biotech CDMO (Contract Developing and Manufacturing Organisation), specialising in R&D Services, process development and production of mAbs, enzymes, proteins, nanodrugs, ADCs and F&F. GTP Bioways Group, with multiple locations across France, specializes in delivering comprehensive services to biopharmaceutical companies. From preclinical development to commercial stages, the group focuses on utilizing cutting-edge technologies to advance innovative therapies.

See the rest here:
Olon Group Announces the Acquisition of GTP Bioways Group

Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication

By Embryonic Stem Cells

St Andrews, UK – 3 July 2024 - Pneumagen, a clinical stage biotech company developing Neumifil (HEX17), a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), announces the publication of new preclinical data evaluating Neumifil in a wide range of viral disease models. These preclinical data are published in the peer-reviewed journal, Antiviral Research in a paper entitled, “HEX17(Neumifil): An intranasal respiratory biotherapeutic with broad-acting antiviral activity,” and confirm the potential of Neumifil as a first in class protein-based antiviral prophylactic for respiratory viral infections. The article can be accessed online at https://doi.org/10.1016/j.antiviral.2024.105945.

Read more from the original source:
Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication

Pentixapharm Acquires Target Discovery Business of Glycotope

By Embryonic Stem Cells

WÜRZBURG, Germany and BERLIN, July 03, 2024 (GLOBE NEWSWIRE) -- Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range of malignancies, has announced the execution of an agreement, effective July 1st, to acquire the target discovery business of Berlin-based Glycotope GmbH.

Read the original here:
Pentixapharm Acquires Target Discovery Business of Glycotope

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

By Embryonic Stem Cells

Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need

Originally posted here:
Apollomics Announces Updated Strategic Focus and Leadership Team Changes

CorMedix Inc. Announces Outpatient Availability of DefenCath

By Embryonic Stem Cells

BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath® (taurolidine and heparin) to outpatient dialysis centers and vascular access clinics where patients receive outpatient dialysis and catheter placement services. The outpatient launch coincides with the effective date of July 1st for outpatient reimbursement of DefenCath as directed by the Center for Medicare & Medicaid Services (CMS).

Go here to see the original:
CorMedix Inc. Announces Outpatient Availability of DefenCath

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Embryonic Stem Cells

WESTLAKE VILLAGE, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 325,000 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 55,000 shares of Arcutis’ common stock to 43 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2024, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).

Read the rest here:
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

→←